Criteria for starting a cytotoxic treatment in patients with follicular lymphoma.
| Adapted GELF criteria (FL2000 and PRIMA studies): any one of these criteria . | BNLI criteria:73 any one of these criteria . |
|---|---|
| *Used in the FL2000 but not in the PRIMA study, given the low percentage of patients with this sole criteria in the former studies (G. Salles, personal communication). | |
| High tumor bulk defined by either: | Rapid generalized disease progression in the preceeding 3 months |
| – a tumor > 7 cm | Life threatening organ involvement |
| – 3 nodes in 3 distinct areas each > 3 cm | Renal of macroscopic liver infiltration |
| – symptomatic splenic enlargement | Bone lesions |
| – organ compression | Presence of systemic symptoms or pruritus |
| – ascites or pleural effusion | Hemoglobin < 10 g/dL or WBC < 3.0 × 109/L or platelet counts < 100 × 109/L; related to marrow involvement |
| Presence of systemic symptoms | |
| ECOG performance status >1 * | |
| Serum LDH or β2-microglobulin above normal values | |
| Adapted GELF criteria (FL2000 and PRIMA studies): any one of these criteria . | BNLI criteria:73 any one of these criteria . |
|---|---|
| *Used in the FL2000 but not in the PRIMA study, given the low percentage of patients with this sole criteria in the former studies (G. Salles, personal communication). | |
| High tumor bulk defined by either: | Rapid generalized disease progression in the preceeding 3 months |
| – a tumor > 7 cm | Life threatening organ involvement |
| – 3 nodes in 3 distinct areas each > 3 cm | Renal of macroscopic liver infiltration |
| – symptomatic splenic enlargement | Bone lesions |
| – organ compression | Presence of systemic symptoms or pruritus |
| – ascites or pleural effusion | Hemoglobin < 10 g/dL or WBC < 3.0 × 109/L or platelet counts < 100 × 109/L; related to marrow involvement |
| Presence of systemic symptoms | |
| ECOG performance status >1 * | |
| Serum LDH or β2-microglobulin above normal values | |